STOCK TITAN
  1. Home
  2. News
  3. LLY

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

News
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) has announced that Zepbound™ (tirzepatide) injection, indicated for adults with obesity or those who are overweight and have weight-related medical problems, is now available. Following the FDA approval, Zepbound is accessible in six doses through retail and mail-order pharmacies. Zepbound has been added to the National Preferred Formulary for Express Scripts and Cigna Healthcare, with a commercial savings card program available to help eligible individuals access it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
News
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends tender offer to acquire POINT Biopharma Global Inc. (NASDAQ: PNT) for $12.50 per share in cash, without interest. The offer has been extended until Dec. 15, 2023, to satisfy the minimum tender condition. Approximately 24.75% of the issued and outstanding shares have been tendered as of Dec. 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
acquisition
-
News
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Rhea-AI Summary
Eli Lilly and Company (LLY) announces the FDA approval of Jaypirca (pirtobrutinib) for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Jaypirca is the first and only non-covalent (reversible) BTK inhibitor, offering a new treatment option for patients with CLL or SLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024. The new location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies. This will be the company's third Gateway Labs location, with additional sites located in San Francisco and Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
News
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
Rhea-AI Summary
Alexandria Real Estate Equities, Inc. (NYSE: ARE) and Eli Lilly and Company (NYSE: LLY) are collaborating to expand Lilly's innovative Gateway Labs model to the San Diego life science cluster, providing emerging biotechnology companies with mission-critical, flexible laboratories and essential, integrated nontechnical space, opportunities to collaborate with Lilly, and access to capital through Lilly and its venture network. The new Gateway Labs site will be located in Alexandria's University Town Center (UTC) submarket, aiming to accelerate the growth of the San Diego cluster's next generation of leading life science companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
partnership
-
News
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) to Invest $2.5 Billion in New High-Tech Manufacturing Site in Germany and $100 Million in Early-Stage Life Sciences Ecosystem
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
News
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends the expiration of the tender offer to acquire all outstanding shares of POINT Biopharma Global Inc. (NASDAQ: PNT) at $12.50 per share in cash. The offer, previously set to expire on Nov. 16, 2023, has been extended to Dec. 1, 2023, to satisfy the minimum tender condition. Regulatory approvals have been obtained, and approximately 26.45% of the outstanding shares have been tendered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
acquisition
-
News
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) obtains NRC Consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license. This follows the completion of Lilly's tender offer to acquire all POINT's common stock for $12.50 per share in cash. The NRC Consent is the final regulatory approval needed for the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
acquisition
-
News
Lilly to Participate in Evercore ISI HealthCONx Conference
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announces participation in the Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D., to join a fireside chat at 3:50 p.m., Eastern time. The live audio webcast will be available on Lilly's Investor website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
News
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
Rhea-AI Summary
Eli Lilly and Company (LLY) extends tender offer to acquire POINT Biopharma Global Inc. (PNT) shares at $12.50 per share in cash, with the expiration now set for Nov. 16, 2023. Approximately 14.16% of the outstanding shares have been tendered as of Nov. 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
acquisition
Stock LLY logo
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

#9 Ranked by Market Cap
#348 Ranked by Stock Gains
#1939 Ranked by Dividends

LLY Stock Data

714.63B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.